Mission Viejo, California – January 30, 2025 – Matregenix Inc., a leader in nanofiber technology, is proud to announce that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the U.S. Air Force. This marks the seventh SBIR/STTR award received by Matregenix from the U.S. Air Force since last year. The goal of this award is to further expand the applications of Matregenix’s MatriNova platform technology for soft tissue repair.
The Air Force Research Laboratory (AFRL) and AFWERX have collaborated to streamline the SBIR and Small Business Technology Transfer (STTR) process by accelerating the timeline from proposal to award, reducing bureaucratic obstacles, and encouraging small businesses to contribute their innovations to the Department of the Air Force’s mission.
Disclaimer: The views expressed are those of the company and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.
About Matregenix
Matregenix Inc., based in Mission Viejo, California, specializes in designing, developing, and manufacturing innovative nanofibrous materials for a wide range of applications, with a focus on filtration and biomedical sectors. The company offers comprehensive development and manufacturing services to advance nanofiber technology and deliver transformative solutions.
About AFWERX
As the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at four hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has executed over 6,200 new contracts worth more than $4.7 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: www.afwerx.com
For more information about Matregenix and its innovations, please visit www.matregenix.com
